Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Graham Mitro"'
Publikováno v:
Experimental and Clinical Transplantation. 18:751-756
OBJECTIVES Immunoglobulin A nephropathy is the most common primary glomerulonephritis in adults. Transplant can be complicated by immunoglobulin A nephropathy recurrence in up to 60% of allografts, sometimes causing graftloss.The use of alemtuzumab f
Autor:
Layth Dahbour, Imran Ali, Ibtissam Gad, Sara Q. Perkins, Sally Itawi, Graham Mitro, Zachary Rotter, Courtney Rusch, Sarah Williams, Xiao-Wei Cherie Tan
Publikováno v:
Journal of Religion and Health. 61:1120-1138
According to many studies, addressing the religious and spiritual (R/S) needs of patient's increase patient satisfaction. One area of interest is how patient self-perceived level of religiosity and spirituality (R/S) influences hospital needs. In thi
Publikováno v:
Experimental and Clinical Transplantation. 18:284-291
OBJECTIVES Alemtuzumab (monoclonal anti-CD52 antibody) provides profound lymphocyte depletion and offers numerous advantages as an induction agent. Elderly recipients (> 65 years old) traditionally have inferior posttransplant outcomes versus younger
Autor:
Bradley J. Buck, Allison Zimmerman, Graham Mitro, Jonathan Demeter, Jorge Ortiz, Michael A. Rees
Publikováno v:
Experimental and Clinical Transplantation. 17:739-748
Objectives Previous research studies have highlighted differences in rejection and graft survival across sexes that favor men. We compared delayed graft function, rejection, graft survival, and overall patient survival between sexes following alemtuz
Autor:
Graham Mitro, Jorge Ortiz, Michael A. Rees, Anthony DeLeonibus, Weikai Qu, Munier Nazzal, Joseph T. Brooks
Publikováno v:
Experimental and Clinical Transplantation. 17:196-201
Objectives Our aim was to assess outcomes in White and African American kidney transplant recipients after induction with alemtuzumab. Materials and methods We performed a retrospective study of 464 patients who received deceased-donor kidney transpl
Publikováno v:
Transplant Immunology. 56:101226
Objectives Alemtuzumab (Ale) is a recombinant monoclonal antibody which binds to CD52 causing profound lymphodepletion, thus allowing its use in renal transplantation induction therapy. However, patients may be at increased risk for opportunistic inf
Autor:
Samer Alharthi, Nastassja Bedford, Michael A. Rees, Madeleine Oliver, Patrick Tenbrink, Amira F. Gohara, Cassandra Zaremba, Jorge Ortiz, Jinling Wu, Graham Mitro, Matthew Jordan
Publikováno v:
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 17(3)
Objectives Posttransplant lymphoproliferative disorder is a known complication of solid-organ transplant. The use of depleting induction agents has demonstrated varying associations with incidence of posttransplant lymphoproliferative disorder. Alemt
Autor:
Naoru Koizumi, Michael A. Rees, Bilel Gdoura, Jorge Ortiz, Joseph T. Brooks, Graham Mitro, Natasha Ahuja, Kevin Becker
Publikováno v:
Trends in Transplantation. 10
Publikováno v:
Trends in Transplantation. 10
Publikováno v:
Journal of Clinical and Experimental Transplantation.
Introduction: Alemtuzumab, a monoclonal antibody used in approximately 13% of kidney transplants, allows for early glucocorticoid withdrawal. High risk patients, defined by a presence of elevated Panel Reactive Antibody (PRA), are at greater risk for